DiaSorin, the diagnostics big, closed the first quarter with substantially stable revenues, margins and profit down from a year earlier.
The company closed the period with a profit of 20,5 million (22,5 million in the first quarter of 2012), an Ebitda of 41,6 million (44,1 million, margin of 39,3% and 41,3 % net of the molecular business) and revenues of 105,8 million (105,7 million a year earlier, +0,2% at current exchange rates, +1,3% at constant exchange rates).
The balance sheet is good. In fact, the net financial position rose by 25 million euros to 72,2 million, while free cash flow increased to 25,2 million compared to 16,5 million in the first quarter of 1. The company confirmed all targets for the full year, in particular revenues up between 2% and 4% at constant exchange rates compared to 2012 and a gross operating margin comparable, again at constant exchange rates, to that of 2012 in absolute terms.
